A 52-year-old woman from Delhi presents to the emergency department with acute onset substernal chest pain for 1.5 hours, associated with nausea and diaphoresis. She has a history of hypertension and type 2 diabetes. On examination: BP 165/95 mmHg, HR 88/min, RR 18/min. Her 12-lead ECG shows ST elevation of 4 mm in leads V1–V4 with reciprocal ST depression in leads II, III, and aVF. Cardiac biomarkers are negative at presentation. She is allergic to aspirin (documented anaphylaxis). What is the most appropriate antiplatelet regimen for this patient?

Explanation

## Clinical Scenario Analysis This is an **anterior wall STEMI** (ST elevation in V1–V4 with reciprocal changes) in a patient with **documented aspirin anaphylaxis**. The challenge is to provide dual antiplatelet therapy without aspirin. ## Aspirin Allergy in Acute STEMI **Key Point:** In patients with true aspirin anaphylaxis, aspirin MUST be avoided. However, dual antiplatelet therapy (DAPT) is still mandatory. The second P2Y12 inhibitor must be selected carefully based on efficacy and safety profile. **High-Yield:** Ticagrelor is the preferred P2Y12 inhibitor when aspirin cannot be used because: - Rapid onset of action (30 minutes) - More potent platelet inhibition than clopidogrel - Superior outcomes in acute coronary syndromes (PLATO trial) - Can be used as monotherapy in aspirin-allergic patients ## Comparison of P2Y12 Inhibitors in Aspirin-Allergic Patients | Agent | Loading Dose | Maintenance | Onset | Efficacy | Aspirin-Free Use | |-------|--------------|-------------|-------|----------|------------------| | **Ticagrelor** | 180 mg | 60 mg BD | 30 min | High | **Preferred** | | Clopidogrel | 600 mg | 75 mg OD | 2–6 hrs | Moderate | Acceptable but slower | | Prasugrel | 60 mg | 5–10 mg OD | 30 min | High | **Contraindicated** in age ≥75 or weight <60 kg; not first-line without aspirin | | Acetaminophen | — | — | — | None | Not an antiplatelet agent | **Clinical Pearl:** Prasugrel is a potent P2Y12 inhibitor but is **contraindicated as monotherapy** without aspirin in acute coronary syndromes per ACC/AHA guidelines. It requires dual therapy with aspirin for efficacy and safety. ## Management Algorithm for Aspirin-Allergic STEMI ```mermaid flowchart TD A[STEMI diagnosis confirmed]:::outcome --> B{Aspirin allergy?}:::decision B -->|No| C[Aspirin 325 mg<br/>+ P2Y12 inhibitor]:::action B -->|Yes| D{Type of allergy?}:::decision D -->|Anaphylaxis/<br/>Stevens-Johnson| E[Ticagrelor 180 mg loading<br/>+ 60 mg BD maintenance]:::action D -->|Rash/GI upset| F[Consider aspirin<br/>with premedication]:::action E --> G[Proceed to PCI]:::action F --> G G --> H[Reperfusion achieved]:::outcome ``` ## Why Ticagrelor is Optimal Here 1. **Rapid onset:** Achieves platelet inhibition within 30 minutes, critical in acute STEMI. 2. **Monotherapy efficacy:** Unlike prasugrel, ticagrelor has proven efficacy without aspirin in ACS. 3. **Superior outcomes:** PLATO trial demonstrated lower cardiovascular death/MI/stroke with ticagrelor vs. clopidogrel. 4. **No age/weight restrictions:** Unlike prasugrel, safe in this 52-year-old woman. **Warning:** Acetaminophen is NOT an antiplatelet agent — it is an analgesic and antipyretic with no anticoagulant or antiplatelet properties. Using it as a substitute is a dangerous misconception. [cite:Harrison 21e Ch 297]